CALSNIC-2 (Canadian ALS Neuroimaging Consortium Study)

Nov 19, 2021

Research Studies

Our Research / All Studies / CALSNIC-2 (Canadian ALS Neuroimaging Consortium Study)

Study Title

CALSNIC-2 (Canadian ALS Neuroimaging Consortium Study)

Enrollment Status

Completed

Principal Investigators

PI: Sanjay Kalra, MD, PhD (University of Alberta)Site-PI: Michael Benatar, MD, PhD

Study Type

Observational

Goals

  • Investigate, in a multi-center fashion, the usefulness of advancing magnetic resonance imaging (MRI) techniques as potential biomarkers for ALS.

Enrolling

ALS patients, Controls

Eligibility

Click to Expand

Affected: Individuals affected with ALS or a related neurodegenerative disorder, including ALS-FTD, PLS, and PMA.
Controls: Healthy controls 40-80 years old.

Study Involvement

Click to Expand

3 half-day study visits at UMiami over an 8-month period

  • Brief family and medical history review
  • MRI Scan
  • Neuropsychological testing
  • Speech Testing
  • Neurological Exam (Affected Participants only)
  • Breathing Testing (Affected Participants only)

Contact

ALSresearch@med.miami.edu

Links

https://clinicaltrials.gov/ct2/show/NCT03362658

Primary Funding Source

ALS Canada

Related Publications

Click to Expand

Bharti K, J Graham S, Benatar M, Briemberg H, Chenji S, Dupré N, Dionne A, Frayne R, Genge A, Korngut L, Luk C, Zinman L, Kalra S; Canadian ALS Neuroimaging Consortium (CALSNIC). Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States. PLoS One. 2022 Jun 16;17(6):e0269154.

https://pubmed.ncbi.nlm.nih.gov/35709100

Related Presentations & Lectures

Click to Expand

McMillan CT (presenter), Wuu J, Hennessy L, Placek K, Clinical Research in ALS (CRiALS) Study, Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Canadian ALS Neuroimaging Consortium (CALSNIC), Quinn C, Elman L, Grossman M, Rampersaud E, Wu G, Taylor JP, Kalra S, Benatar M. Frequency, hazard, and genetic risk factors of cognitive impairment in amyotrophic lateral sclerosis (ALS). Invited presentation at the International Neuropsychological Society Annual Meeting (virtual), Feb 2-5, 2021.